

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:
.....
Fax Number:	Fax Number:

Olaparib

Initial application — Ovarian cancer

Applications only from a medical oncologist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/>	Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer														
and															
<input type="checkbox"/>	There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation														
and															
<table border="1"><tr><td><input type="checkbox"/></td><td>Patient has newly diagnosed, advanced disease</td></tr><tr><td>and</td><td></td></tr><tr><td><input type="checkbox"/></td><td>Patient has received one line** of previous treatment with platinum-based chemotherapy</td></tr><tr><td>and</td><td></td></tr><tr><td><input type="checkbox"/></td><td>Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen</td></tr></table>		<input type="checkbox"/>	Patient has newly diagnosed, advanced disease	and		<input type="checkbox"/>	Patient has received one line** of previous treatment with platinum-based chemotherapy	and		<input type="checkbox"/>	Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen				
<input type="checkbox"/>	Patient has newly diagnosed, advanced disease														
and															
<input type="checkbox"/>	Patient has received one line** of previous treatment with platinum-based chemotherapy														
and															
<input type="checkbox"/>	Patient's disease must have experienced a partial or complete response to the first-line platinum-based regimen														
or															
<table border="1"><tr><td><input type="checkbox"/></td><td>Patient has received at least two lines** of previous treatment with platinum-based chemotherapy</td></tr><tr><td>and</td><td></td></tr><tr><td><input type="checkbox"/></td><td>Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy</td></tr><tr><td>and</td><td></td></tr><tr><td><input type="checkbox"/></td><td>Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen</td></tr><tr><td>and</td><td></td></tr><tr><td><input type="checkbox"/></td><td>Patient has not previously received funded olaparib treatment</td></tr></table>		<input type="checkbox"/>	Patient has received at least two lines** of previous treatment with platinum-based chemotherapy	and		<input type="checkbox"/>	Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy	and		<input type="checkbox"/>	Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen	and		<input type="checkbox"/>	Patient has not previously received funded olaparib treatment
<input type="checkbox"/>	Patient has received at least two lines** of previous treatment with platinum-based chemotherapy														
and															
<input type="checkbox"/>	Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy														
and															
<input type="checkbox"/>	Patient's disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen														
and															
<input type="checkbox"/>	Patient has not previously received funded olaparib treatment														
and															
<input type="checkbox"/>	Treatment will be commenced within 12 weeks of the patient's last dose of the immediately preceding platinum-based regimen														
and															
<input type="checkbox"/>	Treatment to be administered as maintenance treatment														
and															
<input type="checkbox"/>	Treatment not to be administered in combination with other chemotherapy														

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:
.....
Fax Number:	Fax Number:

Olaparib - continued

Renewal — Ovarian cancer

Current approval Number (if known):.....

Applications only from a medical oncologist or medical practitioner on the recommendation of a medical oncologist. Approvals valid for 12 months.

Prerequisites(tick boxes where appropriate)

- ☐ Treatment remains clinically appropriate and patient is benefitting from treatment
- and
- ☐ No evidence of progressive disease

or

☐ Evidence of residual (not progressive) disease and the patient would continue to benefit from treatment in the clinician's opinion
- and
- ☐ Treatment to be administered as maintenance treatment
- and
- ☐ Treatment not to be administered in combination with other chemotherapy
- and
- ☐ Patient has received one line** of previous treatment with platinum-based chemotherapy

and

☐ Documentation confirming that the patient has been informed and acknowledges that the funded treatment period of olaparib will not be continued beyond 2 years if the patient experiences a complete response to treatment and there is no radiological evidence of disease at 2 years

or

☐ Patient has received at least two lines** of previous treatment with platinum-based chemotherapy

Note: *Note "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.

**A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz